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Abstract  
 
Synthetic lethality has long been proposed as an approach for targeting 
genetic defects in tumours. Despite a decade of screening efforts, relatively 
few robust synthetic lethal targets have been identified. Improved genetic 
perturbation techniques, especially those based on CRISPR-Cas9 gene 
editing, have resulted in renewed enthusiasm for searching for synthetic lethal 
effects that operate in cancer [1]. An implicit assumption behind this 
enthusiasm is that the lack of reproducible targets identified can be attributed 
to the limitations of RNA interference technologies. Here, we argue that a 
bigger hurdle is that most synthetic lethal interactions are not highly penetrant, 
i.e. are not robust in the face of the extensive inter- and intra- molecular 
heterogeneity seen in tumours. We outline strategies for identifying and 
prioritising those synthetic lethal interactions most likely to be highly 
penetrant.  
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Highlights (900 characters, including spaces to be submitted as separate 
word doc) 
 
 The development of CRISPR-Cas9 technologies has caused renewed 
enthusiasm for identifying synthetic lethal effects that operate in cancer 
 Whilst some of this enthusiasm is warranted, we highlight the one 
factor limits the utility of synthetic lethal interactions as cancer 
treatments – most synthetic lethal effects are private to individual 
model systems and display incomplete penetrance 
 Experimental and computational methods for defining synthetic lethal 
penetrance are discussed  
 We predict the biological principles that might determine the extent of 
synthetic lethal penetrance 
 
The search for synthetic lethality in cancer  
 
Searching for “synthetic lethality” and “cancer” in Pubmed will reveal a 
plethora of review articles that detail how a genetic phenomenon first 
observed in model organisms has led to the development of novel therapeutic 
approaches in cancer. ‘Synthetic lethality’ (see Glossary) was initially used to 
describe an incompatibility between pairs of alleles in fruit flies, but has 
broadly come to indicate any instance where perturbation of two genes 
individually is well tolerated but in combination results in cell death. The first 
clinical application of this concept led to the regulatory approval of a drug 
class, known as PARP inhibitors, for the treatment of breast or ovarian 
cancers with mutations in the BRCA1 or BRCA2 tumour suppressor genes [2]. 
The potential of exploiting synthetic lethality to target tumours has been such 
that many papers have been published identifying synthetic lethal effects 
associated with individual cancer ‘driver’ genes. These ‘gene centric’ efforts 
have been complemented by near industrial scale ‘unbiased’ efforts to map 
the genetic dependencies of large panels of tumour cell lines [3-6]. These 
studies provide an overview of the genes necessary for the growth of 
individual cell lines and, in combination with genotype information, can be 
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used to identify synthetic lethal effects. The ultimate goal of these efforts is to 
identify vulnerabilities in human cancers that can be exploited using drugs. 
 
Mapping out the various synthetic lethal effects that operate in human cancer 
is clearly a worthwhile pursuit. Despite some major advances in developing 
treatments that target specific vulnerabilities in cancers, the vast majority of 
patients are still treated with approaches that could be grouped into one of 
three categories; remove the tumour (surgery), poison it slightly more than 
normal tissue is harmed (chemotherapy) or irradiate the tumour 
(radiotherapy), hoping that any deleterious effect on normal tissue is limited. 
The relative paucity of targeted treatment approaches (i.e. those that are 
based on an understanding of the molecular biology of the individual’s 
disease) is such that new targets are sorely needed. There was much hope 
that the exploitation of synthetic lethality would deliver some of these targets 
[7, 8]. Of course, the gap between hope and reality has been somewhat 
greater than many imagined - but why? Why, after a decade or so of 
concerted effort aimed at developing synthetic lethal treatments for cancer, 
have we only a handful of successful examples? 
 
Much of the blame has been attributed to technical problems – especially 
those associated with RNA interference (RNAi), until very recently the primary 
workhorse technology used to identify synthetic lethal effects. RNAi 
approaches are limited by “off-target” effects, where the RNAi reagent inhibits 
additional genes to the target gene of interest (GoI), as well as silencing 
efficiency issues, where the RNAi reagent does not appear to inhibit the GoI 
to any great extent. Both of these issues have almost certainly led to a series 
of false positives and false negatives in synthetic lethal experiments [9]. Much 
enthusiasm has thus been attributed to newer technologies that exploit 
CRISPR-Cas9 gene editing, where targeting efficiency is often greater and 
where off-target effects have somewhat less impact [1]. 
 
However, we would argue that the technical aspects of approaches such as 
RNAi, whilst somewhat limiting, are not necessarily the greatest factor that 
has limited the search for SL effects with clinical utility. Perhaps of greater 
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importance is the issue of penetrance, described below, which will remain a 
key issue, even with the application of CRISPR based approaches. 
 
The problem with synthetic lethality: incomplete penetrance  
 
In 2011, we and others highlighted that one factor limiting the utility of 
synthetic lethal interactions as cancer treatments is the extent to which these 
effects are dependent upon the genetic background in which they are 
measured [10]. We proposed that the synthetic lethal effects that are readily 
abrogated by changes in additional genes (soft synthetic lethal effects 
Figure 1) would not be as ideal as cancer therapy targets when compared to 
synthetic lethal interactions that are relatively resilient to additional molecular 
changes (hard synthetic lethal effects [10]) (Figure 1C). These concepts of 
hard and soft synthetic lethality are really an extension of the concept of 
penetrance. When used in population genetics, penetrance describes the 
fraction of individuals carrying a particular genetic marker who also exhibit an 
associated phenotype. When applied to synthetic lethality in cancer, we 
propose the term synthetic lethal penetrance (SLP, see Glossary) be used 
to describe the fraction of tumour cell clones with a specific genetic alteration 
(e.g. a cancer driver gene mutation) that undergo cell death when a synthetic 
lethal target is inhibited. Ideally, synthetic lethal treatments should have 
complete penetrance (Figure 1D) with the presence of the driver gene and 
inhibition of its synthetic lethal partner always leading to tumour cell death, 
regardless of the rest of the molecular composition of the tumour cell (the 
reverse of this scenario is incomplete penetrance). What is perhaps more 
realistic is that we only select highly penetrant effects for clinical assessment 
and disregard SL effects with low penetrance before these reach the clinic. 
 
Despite the importance of assessing the penetrance of synthetic lethal 
interactions, it is clear that this issue has received far less attention than 
improvements in gene perturbation approaches. Even in model organisms 
such as budding yeast, where large scale synthetic lethal screens have been 
performed for over a decade, most screens are performed in a single defined 
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genetic background. This means that we have relatively little idea of how 
dependent synthetic lethal effects are upon their genetic background, or how 
penetrant they might be across different backgrounds [11]. 
 
In cancer, the oncogene KRAS is perhaps the gene most widely screened for 
SL interactions (reviewed in [12]). Despite the large number of screens 
performed, there are very few examples of KRAS SLs that replicate across 
multiple, distinct, studies [12, 13]. As most screens have been performed 
using RNAi based approaches, much of the lack of reproducibility has been 
attributed to the limitations of this technology and to variations in the 
experimental approaches used [9, 13]. However, a recent study suggests this 
might not be the key issue. Elledge and colleagues performed genome-wide 
CRISPR synthetic lethal screens in two pairs of colorectal tumour cell lines to 
identify KRAS SLs [14]; despite the use of CRISPR and the similarity of the 
experimental approach, most SLs identified were private to a single cell line. 
This suggests that neither the limitations of RNAi nor differences in screening 
approaches are sufficient to explain the variation in identified SLs. 
 
Recently two groups have developed pipelines to identify genetic interactions 
through combinatorial CRISPR screening (i.e. inhibiting two genes 
simultaneously) and applied these approaches to the analysis of multiple 
tumour cell lines (TCLs) [15, 16]. In both cases, many observed SLs were 
cell-line specific, with Shen and colleagues noting that only ~10% of the SLIs 
identified were observed in more than one TCL [15]. To get a more accurate 
picture of the cell-type specificity of SLs, statistical approaches that take into 
account experimental reproducibility are required, similar to those developed 
to estimate condition specific genetic interactions in yeast [17]. Nevertheless, 
it seems that many SLs are TCL specific.  
 
Consistent with these preliminary observations in TCLs are results in model 
organisms, where it has been shown that many pairwise genetic interactions 
(including SLs) are modified by the deletion of additional genes [18-20] and 
many genetic interactions are only observed in a specific genetic background 
[21, 22]. 
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Reasons for incomplete penetrance (Figure 1E) 
Cell type specific networks. The extensive variation in the gene-regulatory 
and signalling networks that are active in different cell types is a likely 
explanation for some of the tissue specificity of targeted agents in cancer. A 
well-established example involves addiction to the BRAF oncogene - 
melanoma cells with activating mutations of BRAF are highly sensitive to its 
inhibition but colorectal cancer cells with the same mutation are relatively 
insensitive [23]. This has been attributed to differential wiring of the signalling 
networks in the two cancer types. Such differences in cell-type specific 
networks likely impact synthetic lethal interactions also. A recent screen 
identified a SL between PREX1 and RAS in a panel of acute myeloid 
leukemia (AML) cell lines but not in other cell types [24]. The authors 
attributed this to differential expression of PREX1 and its paralogs in different 
cell types - AML cell lines express PREX1 but not its paralog TIAM1, which 
was expressed in other cell types. Inducing expression of TIAM1 in AML cell 
lines partially rescued the RAS/PREX1 SLI suggesting differential expression 
patterns may explain cell-type specific SLs. 
Genetic and epigenetic heterogeneity. Even amongst cells from ostensibly 
the same tissue type there can be major genetic and epigenetic heterogeneity 
within and between tumours, which may also account for the variation in 
synthetic lethal effects observed in different tumour cells. A pair of tumour 
cells that share an alteration in a common driver gene may differ in the status 
of many other genes and some SLIs might be abrogated by these additional 
alterations. For example, a recent study identified a SLI between XPO1 and 
KRAS in many lung cancer cell lines, an effect that was reversed by alteration 
of FSTL5, another gene frequently altered in lung adenocarcinomas [25]. 
Such 'synthetic rescue' effects can also be identified in the context of acquired 
resistance to synthetic lethal treatments, e.g. loss of 53BP1 can result in 
resistance of BRCA1 mutated tumours to PARP inhibitors [26]. In contrast to 
the situation where alteration of a specific gene may result in resistance to an 
SL, some SLIs may only be evident in cells with very specific combinations of 
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mutations, e.g. lung cancers cell lines with KRAS mutation and loss-of-
function alterations of KEAP1 are sensitive to inhibition of glutaminase [27].  
Experimental approaches to identify highly-penetrant 
synthetic lethal interactions  
 
Several approaches exist for empirically defining the penetrance of SL effects. 
Most SL screens are initially carried out in single isogenic model systems 
(Figure 3A), which, when used in isolation, merely indicate that the identified 
effects operate in one particular genetic background. They do not provide any 
indication of the penetrance of the effects. An alternative approach is to 
perform screens in a large number of non-isogenic models, classified 
according to the status of the gene of interest (GoI) (Figure 3B), and identify 
those genes whose inhibition selectively inhibits the growth of cell lines with 
alterations in the GoI [13]. The advantage of this approach is that the 
molecular heterogeneity present across the cell line panel used can provide: 
(i) a rigorous test of whether a SL effect is highly penetrant; and (ii) an 
assessment of the SL phenotype in the setting of different co-occurring driver 
mutations (e.g. KRAS & APC, BRCA2 & TP53) that might not be found in 
single model screens.  
 
However, performing and interpreting large-scale non-isogenic screens 
comes at some cost, in both economic and logistic terms. Moreover, the 
associations identified between GoI and SL partners are often artefacts 
caused by some other, often unknown, molecular feature that segregates with 
the driver gene mutation, making a causal association between the GoI and 
the identified effects difficult to establish. This issue could be resolved by the 
use of isogenic screens alongside non-isogenic systems. Alternatively, 
penetrance could be assessed by the use of multiple different isogenic 
systems for the GoI, with each isogenic cell pair being derived from a different 
cell lineage (Figure 3C). This could prove powerful, assuming there is a 
requisite level of molecular heterogeneity between the parental cell lines 
used. To ensure an extreme degree of genetic heterogeneity, such 
approaches could also incorporate isogenic screens from distinct species 
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(e.g. mouse-derived cell). An SL effect that is conserved between distinct 
species is by definition, resilient to the large-scale molecular re-wiring that 
accompanies speciation Finally, one additional method to assessing the 
penetrance of an SL effect might be to carry out synthetic rescue screens in 
isogenic model systems to see how many different molecular mechanisms 
there are of abrogating an SL (Figure 3D).  
 
The idea of exploiting model organisms to identify and validate human SL 
interactions is not new [8] and is still commonly used. Recently, a number of 
groups have successfully mined SL interactions from yeast, which 
encompasses the most comprehensive delineation of SL interactions, to 
identify candidate therapeutic targets in human cancer [28-33]. However, the 
reverse situation, where model organisms are used to assess the resilience of 
a SL interaction identified in human cells, to molecular change, seems an 
approach far less used. There are of course significant issues to consider 
when using a comparative approach. The most obvious is whether model 
organisms have clear orthologs of the human GoI and/or whether molecular 
processes that are specific to human cells exist in model organisms. For 
example, it is difficult to imagine the relevance of modelling metazoan specific 
signalling pathways or cell-cell communication networks, in non-metazoan, 
unicellular yeast. In this case, the use of other metazoans (e.g. C. elegans or 
Drosophila melanogaster), might be more appropriate [34-36]. 
 
Understanding the extent to which SL interactions are conserved across 
species at a global level would be advantageous when evaluating the utility of 
model organisms [30, 37-41]. For example, recent studies have demonstrated 
that only SL interactions involved in particular processes are conserved 
between yeast and human cancer cell lines, notably those involved in 
chromosomal instability [28], limiting the utility of such analysis. Other SL 
interactions that tend to be highly conserved include those whose protein 
products physically interact [37] or function in the same biological process 
(e.g. chromosome segregation) [42], suggesting these might be characteristic 
features of highly penetrant SLs.  
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Using computational approaches that identify highly 
penetrant SL interactions (Figure 4) 
Whilst it is now relatively straightforward to identify potential SLs from LoF 
screens, the steps we have outlined above to distinguish highly penetrant 
from less penetrant SLs are both labour- and time intensive. Computational 
tools to prioritise the most promising candidates would therefore be of great 
value.  
Filtering using prior knowledge. One approach to identifying highly 
penetrant SLs from a set of candidate interactions (e.g those identified in an 
isogenic screen) is to prioritise or filter these SL interactions using prior 
knowledge. Perhaps the simplest approach is to prioritise those candidate 
SLs previously observed in a different context - either with orthologous genes 
in a model organism [30, 42] or in distinct TCLs, as discussed above. The 
BioGRID database describes over half a million genetic interactions observed 
in non-human species [43], while the CancerGD resource details putative SLs 
identified in the majority of large-scale cell line panel screens published to 
date [44]. Such SLs, observed in different cell line panels or across different 
species, are likely to be strong candidates for highly penetrant SLs.  
An attractive alternative to relying on existing genetic screen data is to use the 
wealth of 'omics' profiling data of tumours to identify or prioritise SLs. A 
number of methods have been developed to predict SLs from tumour 
molecular profiles and these could be extended to the task of identifying 
prioritising highly penetrant SLs. Perhaps the best-known approaches involve 
the identification of mutually exclusive genetic alterations - pairs of genes that 
are individually recurrently altered but altered in combination significantly less 
than expected by chance (Figure 3A). One interpretation of such mutually 
exclusive mutations is that the two genes may result in similar phenotypic 
outcomes when mutated and consequently there is no selective advantage to 
both genes being altered simultaneously. An alternative explanation is that the 
pair of genes are not mutated simultaneously because they display a 
synthetic lethal interaction. Although many computational approaches have 
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been developed to identify such mutually exclusive events [45], very few 
examples of mutually exclusive pairs have been experimentally demonstrated 
to reflect SLs [46].  
A limitation to this approach is that both genes must be mutated at a relatively 
high frequency for the results to have any statistical significance. This makes 
it difficult to identify significant mutual exclusivity between genes that are not 
themselves driver genes. Jerby-Arnon et al [47] took an alternative approach 
and focussed on pairs of genes that were rarely both under-expressed in the 
same tumours, thus significantly expanding the set of genes for which 
mutually exclusive alterations could be identified. The recent availability of 
proteomic profiling data for tumours [48] opens up opportunities for the 
identification of mutually exclusive events using protein expression, e.g. 
searching for proteins whose expression is high when a tumour suppressor is 
defective [49]. 
Finally, it may be possible to develop heuristics to prioritise highly penetrant 
SLIs using our knowledge of the functions of individual genes and the physical 
and regulatory interactions between cellular components. These are 
discussed in Text Box 1.  
Modelling approaches to predict SLs. A number of computational and 
mathematical approaches have been developed to model various cellular 
subsystems such as metabolism or signalling. These include flux balance 
analysis (FBA - used to model metabolic networks [50]) and approaches that 
describe regulatory and signalling networks using differential equations or 
boolean logic models [51].  In theory, all of these methods can be used to 
model the consequences of perturbations in individual genes as well as the 
effects of combined gene inhibition. However, in general, methods that are 
based on differential equations or logic models tend to describe the effect of 
gene perturbation on internal cellular states (e.g. the phosphorylation of a set 
of proteins, the expression of a particular gene) rather than cellular 
phenotypes such as proliferation or survival. In contrast, FBA has been used 
extensively to predict the impact of perturbations, including double gene 
deletions, on growth in a variety of systems [50, 52, 53]. To our knowledge it 
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is the only modelling approach that has been used to predict synthetic lethal 
interactions in human cancer (reviewed in [52]). A notable success in this 
regard was the identification of Haem oxygenase as a synthetic lethal partner 
of tumour suppressor fumarate hydratase [53]. 
FBA makes use of curated mathematical representations of cellular 
metabolism that describe the enzymes responsible for each metabolic 
reaction along with the metabolites produced and consumed by it. By making 
a number of assumptions, FBA can calculate the flow of metabolites through 
the represented network and ultimately predict the growth rate of a cell [50]. It 
is especially promising for the identification of highly penetrant SLIs because it 
can be used to model large numbers of combinatorial perturbations but also 
can be adapted to model different genetic backgrounds [54]. However, there 
are some major limitations of FBA. First, only a limited number of genes can 
be modelled using FBA (those whose function can be described in terms of 
reactions catalysed) and consequently predictions have not as yet been made 
for the majority of cancer driver genes. Secondly, the accuracy of the models 
when predicting SLIs is quite limited even for well characterised model 
organisms [50]. However, as our knowledge of metabolic networks expands 
so will the accuracy of the resulting predictions.  
Extending the applications of highly penetrant SLs using guilt-by-
association. One of the most striking observations from genetic interaction 
screens in model organisms has been the tendency of members of the same 
complex or pathway to display similar genetic interactions [55]. This suggests 
that if one member of a complex/pathway is a highly penetrant synthetic lethal 
effect with a particular gene, then there is a high probability that other 
members of the complex will be too. Computational approaches based on this 
'guilt-by-association' principal have been widely exploited to predict SLIs in 
model organisms [56]. As many distinct members of a pathway can be altered 
in different tumours, similar approaches could be applied to expand the 
applications of any highly penetrant SLs identified to additional driver genes. 
For example, the initial identification of synthetic lethality between defects in 
the BRCA1/BRCA2 tumour suppressors and PARP inhibitors led to the 
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subsequent identification of SLs between PARP inhibitors and other tumour 
suppressor proteins that act in concert with BRCA1/BRCA2 in DNA repair [2, 
57]. Similarly, the identification of a SLI between the SWI/SNF complex 
tumour suppressor ARID1A and the DNA repair kinase ATR, led to SLs 
between ATR and other SWI/SNF tumour suppressor genes being identified 
[58, 59] suggesting potential pathway level defects. 
2D or not 2D - that, is the question 
 
Many large-scale screens for synthetic lethality focus on the use of in vitro 
tissue culture (TC) approaches where cells are grown on an adherent surface. 
These “two-dimensional” in vitro TC approaches are often the preferred 
method as they provide a reproducible experimental workflow that is scalable 
to, for example, multi-well plate formats. What is not clear is how well these 
experimental formats replicate the complex, three-dimensional, structure of a 
tumour in situ, including cell-cell interactions that exist in a three-dimensional 
(3D) structure but not in two-dimensional (2D) TC. It seems possible therefore 
that some synthetic lethal effects identified in a 2D setting might be reversed 
in a 3D format (and vice versa), especially those that rely on mechanisms that 
involve cell-cell communication. One might think that those SL effects that 
operate in both 2D and 3D settings might be preferable to those that are 
private to either system. Likewise, for very pragmatic reasons, most large-
scale synthetic lethal screens are in vitro screens and only involve one cell 
type. Again, it is possible that synthetic lethal interactions might be abrogated 
by, for example, tumour cell/stromal cell interactions. With these issues in 
mind, it is clear why all serious target validation efforts include an assessment 
of an in vivo model system that in some way attempts to replicate both the 
three-dimensional structure of a human tumour as well as an interaction with 
the stroma. In most cases, these types of in vivo analysis, such as the use of 
patient derived tumour xenografts (PDX), aren’t yet routinely scalable to be 
used in the large-scale discovery of synthetic lethal effects, but the technical 
barriers preventing this will no doubt be rapidly overcome as improvements in 
in vivo CRISPR-Cas9 mutagenesis, mature. However, the use of these in vivo 
systems do play a key role in the assessment of penetrance. Furthermore, 
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where synthetic lethal interactions fail to be replicated in these models, some 
thought might be given to whether these stromal or three-dimensional 
synthetic rescue effects inform an understanding of the effects of cell-cell 
interaction. 
 
Concluding remarks 
 
The enthusiasm for exploiting the synthetic lethal principle to identify novel 
therapeutic targets in cancer is as high now as it has ever been. Many of the 
advances in gene manipulation technology have fuelled this enthusiasm, as 
has the large-scale delineation of essential gene lists in human tumour cells. 
However, we caution that technologies such as CRISPR-Cas9 screening will 
not be a panacea and an increased focus on discriminating highly penetrant 
synthetic lethal effects from those that are less penetrant is still required. 
Some methods already exist for estimating the penetrance of synthetic lethal 
effects and these could be enhanced by learning and then applying the 
principles that determine penetrance. Computational approaches to this 
question are emerging, which when combined with experimental methods, 
could be very effective.  
 
Outstanding Questions (2000 characters, including spaces, required as 
separate word file using the designated heading) 
 Which biological principles determine whether a synthetic lethal effect 
has complete or incomplete penetrance? 
 Can these principles be determined and used to predict highly 
penetrant synthetic lethal effects? 
 Can refined isogenic systems be developed that better model the 
spectrum of mutations present in human tumours? 
 Can methods be developed that allow high-throughput perturbation 
screens to be performed in vivo at similar scale as in vitro perturbation 
screens? 
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 Can computational approaches replace or compliment empirical 
approaches for defining the penetrance of synthetic lethal effects? 
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Glossary (alphabetical) 
Robustness: the extent to which a phenotype (e.g. synthetic lethality) 
persists in the face of other perturbations in a biological system 
Stromal synthetic rescue effects: Where the activity of non-cancerous 
stromal cells reverses a synthetic lethal effect in a tumour cell, for example, by 
providing a cell survival signal to tumour cells 
Synthetic lethality: where a combination, or synthesis, of gene defects 
causes cell death, but where individual gene defects do not 
Synthetic lethal penetrance (SLP): the fraction of tumour cell clones with a 
specific genetic alteration (e.g. a cancer driver gene mutation) that undergo 
cell death when a synthetic lethal target is inhibited 
Synthetic rescue: where a synthetic lethal effect is reversed, often via an 
additional molecular change 
Three-dimensional synthetic rescue effects: Where the growth of tumour 
cells in a three-dimensional context reverses a synthetic lethal effect 
previously observed in two-dimensional tissue culture 
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Text Box 1. What features might highly penetrant synthetic 
lethal interactions have? 
 
Analyses of genetic interactions in model organisms have identified that SLs 
with certain molecular properties are more likely to be conserved across 
species [38, 42, 60, 61]. For example, SLIs involving kinases and transcription 
factors are more poorly conserved across species than SLIs involving other 
gene types [61]. In contrast, SLIs involving pairs of genes whose protein 
products physically interact tend to be highly conserved [38, 42, 60]. These 
features have been used to develop computational models that predict 
conserved synthetic lethal interactions [42]. It may be possible to develop 
similar heuristics that distinguish highly penetrant effects from those that are 
less penetrant. The below characteristics are largely based upon first 
principles (and might at first glance appear self-evident), but where possible, 
we have exploited existing data to define what might characterise highly 
penetrant effects. 
 
Characteristic 1 – inhibited process must be broadly essential. For a 
highly penetrant SLI, we predict that the combined perturbation of both genes 
disrupts a process that is essential for growth across many cell types (e.g. 
translation, protein degradation, DNA replication). If a process is only required 
in specific cell types than it is very unlikely that a SL which disrupts it will be 
highly penetrant. Alternatively, the process that is perturbed by a highly 
penetrant SL might not be essential in all cell types, but a commonly acquired 
characteristic (or hallmark [62]) of cancer, such as resistance to apoptosis. 
 
Characteristic 2 – genes involved must function in related pathways. For 
a highly penetrant SL, we predict that the two genes involved in the SL should 
function in related biological processes. Often SLs identified in screens 
involve gene pairs with no obvious functional connection between them. 
Anecdotally these SLs seem less likely to replicate across multiple TCLs than 
SLs between gene pairs with a clear functional relationship (e.g. members of 
the same pathway). The closeness of the functional relationship between a 
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gene pair could be calculated as the shortest path between them on an 
integrated molecular interaction network, such as a protein-protein interaction 
network [4]. Such an approach would prioritise SLs involving pairs functioning 
in the same complex (i.e. those most conserved across species) or pathway 
over those functioning in distal processes. 
 
Characteristic 3 – targeted genes must have not have highly cell type 
specific functions. For a highly penetrant SL, we predict that the targeted 
genes should have relatively constant functions across cell types, otherwise 
their perturbation is likely to have very variable phenotypic consequences 
across different tumour cell clones. Many transcription factors regulate the 
expression of different genes in different cell-types, suggesting that perturbing 
a transcription factor may not have similar phenotypic consequences across 
TCLs. In contrast, most subunits of the proteasome complex tend to form part 
of the proteasome in all cell types, suggesting their perturbation may have 
more fixed consequences across cell types. Distinguishing those genes that 
have fixed or variable functions across cells is non-trivial, but recent work 
suggests that analysing the transcriptional consequences of gene perturbation 
in different contexts may prove a useful proxy. Niepel et al [63] analysed the 
transcriptional profiles of multiple breast TCLs in response to perturbations 
and found that while the transcriptional response to certain drug classes 
(HSP90 inhibitors, cell cycle kinases) was relatively constant, other drug 
classes (MAPK inhibitors, PI3K inhibitors) caused cell-type specific 
transcriptional responses. There was some correspondence between the 
variability of the transcriptional response across cell lines and the variability of 
the phenotypic response.  
 
Characteristic 5 –  target genes should have few close paralogs. The 
protein to target therapeutically should have relatively few paralogs (gene 
duplicates) that might otherwise take over its role when its function is 
inhibited. Alternatively, the means of inhibiting the target (e.g. small molecule) 
should inhibit all of the target's paralogs also. 
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Characteristic 6 – synthetic lethal interactions should be conserved 
across species. It seems reasonable to think that SLs that are conserved 
across species barriers and are thus robust in the face of the extensive 
molecular re-wiring that accompanies speciation might be highly penetrant. 
Notably the BRCA/PARP synthetic lethality was observed in hamster, mouse 
and human cell lines [64-66].   
 
Characteristic 7 – Mutual exclusive characteristics. It seems reasonable 
to think that when viewed in a large number of tumours, alterations in highly 
penetrant SL genes in tumours should be mutually exclusive. This mutual 
exclusivity could reflect an absence of synthetic rescue mechanisms and thus 
a highly penetrant SL.  
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Figure legends 
 
Figure 1. Synthetic lethality and synthetic lethal penetrance. A. Synthetic 
lethality. A synthetic lethal interaction, depicted by arrows, operates between 
two genes, A and B. Inactivation of either gene in isolation is compatible with 
cell viability and survival, whereas the combination, or synthesis, in defects in 
A and B causes cell death. B. Soft synthetic lethality. A synthetic lethal 
interaction exists between genes A and B but can be reversed by defects in 
either gene C, D or E. C. Hard synthetic lethality. In contrast to the soft 
synthetic lethality between A and B, the synthetic lethal interaction between 
genes F and G is only reversed by inactivation of H and is relatively resilient in 
the face of additional molecular alterations. D. Synthetic lethal penetrance. 
Genes A and B are synthetic lethal. The effect on cell inhibition caused by 
inactivation of gene B is shown for a fully penetrant effect (left) and an 
incomplete penetrant effect (right). E. Reasons for incomplete penetrance  
 
Figure 2. Experimental approaches for the identification of synthetic 
lethal effects for a genotype of interest. There are three most common 
experimental approaches for identifying synthetic lethal effects using cell line 
models. A. High-throughput perturbation screens on a single isogenic system 
can be utilized for a given genotype of interest where Gene A is wild type 
(blue) or mutant (orange). B. Perturbation screens as in A could be performed 
on a panel of cell lines with extensive molecular heterogeneity annotated 
according to the status of the GoI where Gene A is wild type (blue, n = 10) or 
mutant (orange, n = 10). C. High-throughput perturbation screens on multiple 
isogenic system using different lineages and/or species representing 
extensive molecular heterogeneity, could be utilized for a given genotype of 
interest where Gene A is wild type (blue) or mutant (orange). D. Following the 
identification of a series of synthetic lethal effects (e.g. between Gene A and 
either B, C, D or E) iterative synthetic rescue screens could be performed 
where Gene A and B are simultaneously perturbed and high throughput 
functional screens could be performed to reverse the synthetic lethal effect 
between Gene A and B. The same approach is taken to rescue the synthetic 
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lethal effects between Gene A and C, D or E.  The penetrance of a synthetic 
lethal effect is established by counting the number of molecular routes to 
synthetic rescue with the synthetic lethal effect between Gene A and E being 
demonstrated to be the most penetrant.  
 
Figure 3. Computational methods to identify synthetic lethal effects. A. 
Mutually exclusive mutations may identify potential SLs. Genes A and C are 
mutated in a mutually exclusive fashion, suggesting a potential SL B. Flux 
balance analysis can be used to model metabolic activity. SLs can be 
identified by modelling how pairwise gene knockouts impact growth (centre), 
while synthetic rescue effects can be identified by modelling higher order 
gene knockouts (right) C. Guilt by Association. A hard SL (solid red line) 
involving subunits of distinct protein complexes potentially indicates additional 
SLs between other members of the two complexes (dashed red line) D. 
Shortest Path. SLs between genes with close functional relationships (e.g. 
genes A and B, which physically interact) may be more penetrant than those 
between genes with only indirect connections (e.g. A and E, which are 3 hops 
apart on the protein-interaction network). 
 
 
 
